Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.
Bubs Australia has triumphed in a long-standing legal dispute, winning $26.5 million in arbitration awards against Alpha Group subsidiaries Alice Trading and Willis Trading. The company now faces the challenge of recovering the awarded sums.
The a2 Milk Company has reported robust first-half FY25 results, boosting full-year guidance and declaring its inaugural dividend, underscoring confidence in its growth trajectory.
Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.